Evidence map›Paper›PMID 37636837›Full record

ArticleTherapeutic advances in drug safety2023

Clinical relevance of potential self-medication drug interactions in antineoplastic and immune-modulating therapy among online pharmacy customers.

Florian Schindler, Timo Schinkoethe, Sven Mahner, Thomas Kolben, Rachel Wuerstlein, Carsten Culmsee, Nadia Harbeck, Tanja K Eggersmann

Open access · goldAbstract read
In one paragraph

Article in Therapeutic advances in drug safety, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Florian SchindlerBreast Center, Department of Obstetrics and Gynecology, LMU University Hospital, Munich, Germany.ORCID https://orcid.org/0000-0003-4512-4114
Timo SchinkoetheBreast Center, Department of Obstetrics and Gynecology, LMU University Hospital, Munich, Germany.
Sven MahnerBreast Center, Department of Obstetrics and Gynecology, LMU University Hospital, Munich, Germany.
Thomas KolbenBreast Center, Department of Obstetrics and Gynecology, LMU University Hospital, Munich, Germany.
Rachel WuerstleinBreast Center, Department of Obstetrics and Gynecology, LMU University Hospital, Munich, Germany.
Carsten CulmseeInstitute for Pharmacology and Clinical Pharmacy, Biochemical-Pharmacological Center Marburg, Faculty of Pharmacy, University of Marburg, Marburg, Germany.
Nadia HarbeckBreast Center, Department of Obstetrics and Gynecology, LMU University Hospital, Marchioninistrasse 15, Munich 80333, Germany.
Tanja K EggersmannBreast Center, Department of Obstetrics and Gynecology, LMU University Hospital, Munich, Germany.
Ludwig-Maximilians-Universität München · DEPhilipps University of Marburg · DEUniversity Hospital Schleswig-Holstein · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Modern oral antineoplastic and immune-modulating drugs offer an array of therapeutic advantages, and yet pose challenges in daily use for patients, physicians and pharmacists. In contrast to intravenous administration, these drugs are not subject to direct medical control. Recently, we have seen a huge rise in sales of non-prescription over-the-counter (OTC) medicines Objectives: The aim of this study was to investigate whether the risk of known potential drug-drug interactions between modern oral antineoplastic and immune-modulating drugs and OTC drugs differs between sales in traditional community pharmacies Design: Real-life sales data from community and online pharmacies were used as basis for the analysis. Methods: We determined the most frequently purchased antineoplastic and immune-modulating drug-substances in 14 local community pharmacies within the Munich area, Germany and identified the OTC substance groups that could potentially cause interactions with oncological therapies. Using sales data from 11 local community pharmacies and three online pharmacies, we investigated whether OTC purchases differed between the two sales channels. Results: We identified 10 relevant OTC substance classes and detected significant variations in patients' preferred sales channels between the drug classes. Certain OTC drugs, which seem to be bought more often over the internet, pose risks during antineoplastic and immune-modulating therapy. Conclusion: Patients should therefore be proactively made aware of the corresponding risks in order not to jeopardize the activity of the antineoplastic and immune-modulating drugs and thus the success of their therapy.

Indexed as

antineoplastic therapyDDIsdrug-drug interactionsimmune-modulating therapyonline pharmacyself-medication

Identifiers

PMID37636837
PMCPMC10460262
OpenAlexW4386144680

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.